Bio Rad Laboratories Inc banner

Bio Rad Laboratories Inc
NYSE:BIO

Watchlist Manager
Bio Rad Laboratories Inc Logo
Bio Rad Laboratories Inc
NYSE:BIO
Watchlist
Price: 370.92 USD 0.59% Market Closed
Market Cap: $10B

Wall St Price Targets

BIO Price Targets Summary
Bio Rad Laboratories Inc

Wall Street analysts forecast BIO stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BIO is 336.6 USD with a low forecast of 318.15 USD and a high forecast of 409.5 USD.

Lowest Forecast
Price Target
318.15 USD
14% Downside
Average Forecast
Price Target
336.6 USD
9% Downside
Highest Forecast
Price Target
409.5 USD
10% Upside
Bio Rad Laboratories Inc Competitors:
Price Targets

Revenue
Forecast

2% / Year
Past Growth
2% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
2% / Year
Past Growth
2% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 2%. The projected CAGR for the next 5 years is 2%.

Gross Profit
Forecast

1% / Year
Past Growth
2% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
1% / Year
Past Growth
2% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 1%. The projected CAGR for the next 5 years is 2%.

Operating Income
Forecast

0% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss
0% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 0%. The projected CAGR for the next 5 years is 8%.

Pre-Tax Income
Forecast

12% / Year
Past Growth
-29% / Year
Estimated Growth
Estimates Accuracy
63%
Average Beat
12% / Year
Past Growth
-29% / Year
Estimated Growth
Estimates Accuracy
63%
Average Beat

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 12%. The projected CAGR for the next 3 years is -29%.

Net Income
Forecast

12% / Year
Past Growth
-18% / Year
Estimated Growth
Estimates Accuracy
25%
Average Beat
12% / Year
Past Growth
-18% / Year
Estimated Growth
Estimates Accuracy
25%
Average Beat

Over the last 13 years, the compound annual growth rate for Net Income has been 12%. The projected CAGR for the next 5 years is -18%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is BIO's stock price target?
Price Target
336.6 USD

According to Wall Street analysts, the average 1-year price target for BIO is 336.6 USD with a low forecast of 318.15 USD and a high forecast of 409.5 USD.

What is the Revenue forecast for Bio Rad Laboratories Inc?
Projected CAGR
2%

Over the last 13 years, the compound annual growth rate for Revenue has been 2%. The projected CAGR for the next 5 years is 2%.

What is the Gross Profit forecast for Bio Rad Laboratories Inc?
Projected CAGR
2%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 1%. The projected CAGR for the next 5 years is 2%.

What is the Operating Income forecast for Bio Rad Laboratories Inc?
Projected CAGR
8%

Over the last 13 years, the compound annual growth rate for Operating Income has been 0%. The projected CAGR for the next 5 years is 8%.

What is the Pre-Tax Income forecast for Bio Rad Laboratories Inc?
Projected CAGR
-29%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 12%. The projected CAGR for the next 3 years is -29%.

What is the Net Income forecast for Bio Rad Laboratories Inc?
Projected CAGR
-18%

Over the last 13 years, the compound annual growth rate for Net Income has been 12%. The projected CAGR for the next 5 years is -18%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett